Company

NGM Biopharmaceuticals, Inc.

NGM Biopharmaceuticals develops medicines for cardio-metabolic, liver, cancer, and eye diseases.

About

NGM Biopharmaceuticals develops biologic drug candidates for cardio-metabolic, liver, oncologic, and ophthalmic diseases. Founded in 2008, it is based in San Francisco, US. The Column Group led its USD 122 million Series A funding in July 2024 to support clinical and registrational trials of Aldafermin.

9Funding rounds

5Investors

Sign in to see more

Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.

Sign in